Showing 4761-4770 of 21477 results for "".
- Malnutrition, Health Literacy Linked to HRQoL in Cirrhosishttps://reachmd.com/news/malnutrition-health-literacy-linked-to-hrqol-in-cirrhosis/2488809/Key Takeaways Among patients described as having decompensated cirrhosis at a hospital in Taiyuan, China, those classified as malnourished had poorer health-related quality of life (HRQoL). Adding health literacy significantly increased the variation in HRQoL scores
- Gout Linked to Higher Fracture Rates, Less Bone-Protective Therapyhttps://reachmd.com/news/gout-linked-to-higher-fracture-rates-less-bone-protective-therapy/2488813/Key Takeaways Among patients with gout in American College of Rheumatology registry–Medicare matched comparisons, nonvertebral osteoporotic fracture incidence was higher than among patients with either osteoarthritis or soft-tissue rheumatism. For the gout–osteoarthr
- Fiber-Rich Gluten-Free Foods: No Overall Glucose Benefit in Pilothttps://reachmd.com/news/fiber-rich-gluten-free-foods-no-overall-glucose-benefit-in-pilot/2488807/Key Takeaways Among women with celiac disease in a remotely conducted Norwegian comparison, glucose iAUC did not improve significantly with fiber-rich experimental foods versus benchmark gluten-free foods. Glucose at the 120-minute OGTT time point fell more with expe
- Esketamine Linked to Less Day-3 Sleep Disruption After Oocytehttps://reachmd.com/news/esketamine-linked-to-less-day-3-sleep-disruption-after-oocyte/2488808/Key Takeaways Among women undergoing transvaginal oocyte retrieval under intravenous anesthesia, esketamine was associated with significantly less day-3 sleep disturbance than saline. Day-1 sleep disturbance and postoperative anxiety and depression scores did not dif
- Galderma Launches Restorative Eye Complex with TriHex+ Proprietary Technologyhttps://reachmd.com/news/galderma-launches-restorative-eye-complex-w-trihex-proprietary-technology/2488824/Galderma announced the US launch of ALASTIN Restorative Eye Complex with TriHex+, an updated topical formulation designed to address visible signs of aging across the upper eyelids, under-eye area, and crow's feet. The product incorporates the company's TriHex+ platf
- SCC-DBS Pathway Engagement Linked to Depression Responsehttps://reachmd.com/news/scc-dbs-pathway-engagement-depression-response/2488787/Key Takeaways Among patients with treatment-resistant depression receiving bilateral SCC-DBS, responders had less spatial variation in reconstructed activated-tissue volumes than nonresponders. A focal stimulation cluster was associated with improvement in depressive sympt
- Lutikizumab Meets Primary Endpoint in Phase 3 Hidradenitis Suppurativa Trialhttps://reachmd.com/news/lutikizumab-meets-primary-endpoint-in-phase-3-hidradenitis-suppurativa-trial/2488774/AbbVie announced positive topline results from the Phase 3 INTREPID trial evaluating lutikizumab, an investigational dual IL-1α/IL-1β antagonist, in adults and adolescents with moderate-to-severe hidradenitis suppurativa (HS). The randomized, double-blind, placebo-co
- AI Endoscopic Depth Assessment for Early Gastric Cancerhttps://reachmd.com/news/ai-endoscopic-depth-assessment-for-early-gastric-cancer/2488771/Key Takeaways Among resected early gastric cancers in a retrospective cohort at one Japanese hospital, the classifier exceeded its prespecified 75% lower-confidence-bound sensitivity criterion for mucosal disease. Specificity for pathologically submucosal disease was
- Undeclared Clobetasol Found in 6 of 18 Selected OTC Skin Productshttps://reachmd.com/news/undeclared-clobetasol-found-in-6-of-18-selected-otc-skin-products/2488772/Key Takeaways Undeclared active ingredients were found among deliberately selected online OTC skin products marketed for persistent skin complaints or hyperpigmentation. Clobetasol appeared in every positive product, and its highest measured concentration exceeded th
- FDA Accelerates Dostarlimab Approval for MSI-H/dMMR Rectal Cancerhttps://reachmd.com/news/fda-accelerates-dostarlimab-approval-for-msi-hdmmr-rectal-cancer/2488775/Key Takeaways The FDA granted accelerated approval for adults with MSI-H or dMMR stage II/III locally advanced rectal cancer identified by an FDA-authorized solid-tumor test. Independent review found sustained clinical complete responses after dostarlimab, without es